Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB),

U.S. stock indexes are drifting around their records as hopes hold that the economy can pull off the rare feat of getting painfully high inflation under control without a recession. The S&P 500 was up 0.